Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
View/ Open
Author
Wu, Hong
Wang, Aoli
Zhang, Wei
Wang, Beilei
Chen, Cheng
Wang, Wenchao
Hu, Chen
Ye, Zi
Zhao, Zheng
Wang, Li
Li, Xixiang
Yu, Kailin
Liu, Juan
Wu, Jiaxin
Yan, Xiao-E
Zhao, Peng
Wang, Chu
Yun, Cai-Hong
Liu, Jing
Chen, Liang
Liu, Qingsong
Note: Order does not necessarily reflect citation order of authors.
Metadata
Show full item recordCitation
Wu, H., A. Wang, W. Zhang, B. Wang, C. Chen, W. Wang, C. Hu, et al. 2015. “Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.” Oncotarget 6 (31): 31313-31322.Abstract
Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M ‘gatekeeper’ mutant cells and not active to wild-type EGFR NSCLC cells. Ibrutinib strongly affected EGFR mediated signaling pathways and induced apoptosis and cell cycle arrest (G0/G1) in mutant EGFR but not wt EGFR cells. However, ibrutinib only slowed down tumor progression in PC-9 and H1975 xenograft models. MEK kinase inhibitor, GSK1120212, could potentiate ibrutinib's effect against the EGFR (L858R/T790M) mutation in vitro but not in vivo. These results suggest that special drug administration might be required to achieve best clinical response in the ongoing phase I/II clinical trial with ibrutinib for NSCLC.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741607/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318693
Collections
- FAS Scholarly Articles [18256]
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)